|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 150 South Saunders Road |
Address2 |
|
| City | Lake Forest |
State | IL |
Zip Code | 60045 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 401103901-12
|
||||||||
|
6. House ID# 431440001
|
||||||||
| TYPE OF REPORT | 8. Year | 2019 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Marilyn Vetter, Vice President, Government & Public Affairs |
Date | 10/21/2019 2:25:38 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Regulation CMS-1711-P "CY 2020 Home Health Prospective Payment System Rate Update; Home Health Value-Based Purchasing Model; Home Health Quality Reporting Requirements; and Home Infusion Therapy Requirements," all provisions. Issues related to the implementation of PL 111-148 "Patient Protection and Affordable Care Act," all provisions pertaining to the Center for Medicare and Medicaid Innovation (CMMI) and federal programs. Issues related to drug pricing transparency. HR 2296 FAIR Drug Pricing Act of 2019, all provisions. S 4743 Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019, all provisions. HR 2113 Prescription Drug STAR Act, all provisions. HR 2296 More Efficient Tools to Realize Information for Consumers (METRIC) Act, all provisions. Issues related to improved oversight regulatory requirements for 340B hospital reporting, excluding Federal Grantees. Issues related to the implementation of PL 97-414 "Orphan Drug Act," all provisions. H Res 242 Orphan Drug Act, all provisions. HR 1503 "Orange Book Transparency Act of 2019," provisions in Section 2 relating to the Orange Book. HR 107 To amend title XIX of Social Security Act, all provisions. Issues related to creating a cystinosis disease awareness day on May 7th. Office of the Inspector General (HHS) Rule OIG-0936-P, all provisions pertaining to Fraud and Abuse; Issues related to the removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees. CMS Rule CMS-5528-ANPRM relating to Medicare Program, all provisions. Issues related to an International Pricing Index Model for Medicare Part B Drugs. Issues related to importation of pharmaceuticals. S 102 " Prescription Drug Price Relief Act of 2019," all provisions. HR 3 " Lower Drug Costs Now Act of 2019," all provisions.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Beth |
Rada |
|
|
|
Eli |
Kogan |
|
|
|
Parul |
Patel |
|
|
|
Jordan |
Chapman |
|
|
|
Brent |
Fisk |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Horizon Therapeutics USA, Inc. (FKA Horizon Pharma USA, Inc.) is a US domestic subsidiary of a foreign parent. All lobbying efforts, while not controlled, supervised, or directed by the parent, benefit the parent tangentially.
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |